Elanco Animal Health Incorporated Proceeds from Lines of Credit
Elanco Animal Health Incorporated (ELAN) reported Proceeds from Lines of Credit of $250.00 million for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-07.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2023-08-07
- Elanco Animal Health Incorporated proceeds from lines of credit for the quarter ending 2023-06-30 was $50.00M, a 90.00% decline year-over-year.
- Elanco Animal Health Incorporated proceeds from lines of credit for the quarter ending 2023-03-31 was $200.00M, a 217.46% increase year-over-year.
- Elanco Animal Health Incorporated proceeds from lines of credit for the quarter ending 2022-12-31 was $0.00.
- Elanco Animal Health Incorporated proceeds from lines of credit for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- Elanco Animal Health Incorporated proceeds from lines of credit for fiscal 2022 was $563.00M, a 12.60% increase from fiscal 2021.
- Elanco Animal Health Incorporated proceeds from lines of credit for fiscal 2021 was $500.00M.
- Elanco Animal Health Incorporated proceeds from lines of credit for fiscal 2020 was $0.00.
- Elanco Animal Health Incorporated proceeds from lines of credit for fiscal 2019 was $0.00.
| Period end | Proceeds from Lines of Credit 3 month | Proceeds from Lines of Credit 3 month as first filed | Proceeds from Lines of Credit 6 month | Proceeds from Lines of Credit 9 month | Proceeds from Lines of Credit 9 month as first filed | Proceeds from Lines of Credit 12 month |
|---|---|---|---|---|---|---|
| 2023-06-30 | $50.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $250.00M 10-Q · filed 2023-08-07 | $250.00M derived: sum of 3 quarters · filed 2023-08-07 | $250.00M derived: sum of 4 quarters · filed 2023-08-07 | ||
| 2023-03-31 | $200.00M 10-Q · filed 2023-05-09 | $200.00M derived: sum of 2 quarters · filed 2023-05-09 | $200.00M derived: sum of 3 quarters · filed 2023-05-09 | $700.00M derived: sum of 4 quarters · filed 2023-08-07 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $0.00 derived: sum of 2 quarters · filed 2023-03-01 | $500.00M derived: sum of 3 quarters · filed 2023-08-07 | $563.00M 10-K · filed 2023-03-01 | ||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $500.00M derived: sum of 2 quarters · filed 2023-08-07 | $563.00M 10-Q · filed 2022-11-08 | $563.00M derived: sum of 4 quarters · filed 2023-08-07 | ||
| 2022-06-30 | $500.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $563.00M 10-Q · filed 2023-08-07 | $563.00M derived: sum of 3 quarters · filed 2023-08-07 | $913.00M derived: sum of 4 quarters · filed 2023-08-07 | ||
| 2022-03-31 | $63.00M 10-Q · filed 2023-05-09 | $63.00M derived: sum of 2 quarters · filed 2023-05-09 | $413.00M derived: sum of 3 quarters · filed 2023-05-09 | $413.00M derived: sum of 4 quarters · filed 2023-05-09 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $350.00M derived: sum of 2 quarters · filed 2023-03-01 | $350.00M derived: sum of 3 quarters · filed 2023-03-01 | $500.00M 10-K · filed 2023-03-01 | ||
| 2021-09-30 | $350.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $350.00M derived: sum of 2 quarters · filed 2022-11-08 | $500.00M 10-Q · filed 2022-11-08 | $250.00M 10-Q · filed 2021-11-05 | $500.00M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $150.00M 10-Q · filed 2022-08-08 | $150.00M derived: sum of 3 quarters · filed 2023-03-01 | |||
| 2021-03-31 | $150.00M 10-Q · filed 2022-05-09 | $50.00M 10-Q · filed 2021-05-07 | $150.00M derived: sum of 2 quarters · filed 2023-03-01 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $0.00 10-K · filed 2023-03-01 | ||||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-05 | |||||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-07 | |||||
| 2019-12-31 | $0.00 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |